Huadong Medicine News

Research reports on mining opportunities | Guolian: Initiating a "buy" rating for Huadong Medicine, with visible results from its innovative transformation.

Gelonghui FinanceNov 22 14:34

East China Pharmaceutical (000963): Innovation and Globalization - Two-wheel Drive High Quality Growth

guolianNov 21 18:27

East China Pharmaceutical (000963): Bailing Mining Risk Landed, GLP-1 is about to go overseas

htscNov 12 20:42

East China Pharmaceutical (000963): Abundant reserves of domestic medical and aesthetic slowing weight loss products

Yangtze SecuritiesNov 10 20:32

Huadong Pharmaceutical (000963): The performance is in line with expectations, and the industrial profit performance is impressive

Huachuang SecuritiesNov 10 13:47

Deep* Company* Huadong Pharmaceutical (000963): Performance maintains steady growth, innovation pipeline continues to advance

boc internationalOct 29 07:31

East China Pharmaceutical (000963): Innovation and progress in multiple fields, rich attention to engineering and medical and aesthetic flexibility

cscOct 27 19:46

Huadong Pharmaceutical (000963) 2024 Third Quarterly Report Review: Pharmaceutical performance is outstanding, medical beauty is under slight pressure

Western SecuritiesOct 26 14:21

East China Pharmaceutical (000963): Performance is in line with expectations, the industrial and micro sector is growing rapidly

Galaxy SecuritiesOct 25 00:00

East China Pharmaceutical (000963): Overall performance has maintained steady growth, and the innovation pipeline layout continues to be rich

sinolinkOct 24 00:00

East China Pharmaceutical (000963): Q2 performance slightly exceeded expectations, steady industrial growth and abundant reserves of medical and aesthetic products

Aug 22 19:36

East China Pharmaceutical (000963): Profit-side performance is impressive, and the overall profit contribution of the medical and aesthetic sector is steadily increasing

Aug 21 00:00

Huadong Pharmaceutical (000963): Steady growth in performance and increased innovation pipeline

Aug 20 07:36

Huadong Pharmaceutical (000963): Q2 performance exceeded expectations, innovation and transformation continued to be realized

Aug 20 00:00

Huadong Pharmaceutical (000963): Net profit slightly exceeded expectations, and BD continues to land

Aug 19 07:46

Huadong Pharmaceutical (000963): The results of the 24-year mid-year report slightly exceeded market expectations

Aug 18 00:00

Huadong Pharmaceutical (000963): 2Q24 profit growth accelerated

Aug 16 19:01

Huadong Pharmaceutical (000963): Profit growth slightly exceeds market expectations and continues to increase self-defense and CAR-T

Aug 16 12:46

East China Pharmaceutical (000963): Various sectors continue to grow steadily and the innovation pipeline layout continues to be rich

Aug 16 12:01

Huadong Pharmaceutical (000963): Performance growth slightly exceeds expectations and continues to expand R&D and innovation pipeline

Aug 16 00:00